Landos Biopharma(LABP) - 2023 Q2 - Quarterly Report

Financial Position - The company reported an accumulated deficit of $143.4 million as of June 30, 2023, and expects to incur substantial operating losses for at least the next several years [78]. - As of June 30, 2023, the company had cash, cash equivalents, and marketable securities totaling $44.7 million, which is expected to fund operations into the first half of 2025 [78]. - The company has not generated any revenue from product sales since its inception in 2017 [77]. - The company expects to incur significant expenses and operating losses for the foreseeable future, necessitating additional capital to fund operations [96]. - The company currently has no credit facility or committed sources of capital, which may limit its ability to finance operations [111]. - If additional capital is raised through equity or convertible debt securities, existing stockholders may experience significant dilution [111]. - The company may need to relinquish valuable rights to technologies or future revenue streams if it raises funds through third-party collaborations or licensing arrangements [111]. Research and Development - The company initiated the NEXUS trial, a Phase 2 proof-of-concept clinical trial for NX-13 in patients with moderate to severe ulcerative colitis, with top-line data expected by the fourth quarter of 2024 [73]. - NX-13 showed favorable safety and tolerability profiles in a Phase 1b trial, with clinical improvement signals observed as early as two weeks [73]. - The company has several preclinical product candidates, including LABP-73 for asthma and COPD, LABP-66 for multiple sclerosis and Alzheimer's disease, and LABP-69 for diabetic nephropathy and rheumatoid arthritis [74]. - Research and development expenses are anticipated to decrease in 2023 relative to 2022 due to the wind-down of previous clinical trial activities [81]. - Research and development expenses decreased to $2.5 million for the three months ended June 30, 2023, from $6.6 million in the same period of 2022, a reduction of $4.1 million attributed to decreased clinical activities [91]. - For the six months ended June 30, 2023, research and development expenses were $5.8 million, down from $17.4 million in 2022, reflecting a decrease of $11.6 million primarily due to reduced clinical activities [92]. - The company anticipates that expenses will increase in connection with ongoing research and development activities, particularly for clinical trials [105]. Operating Expenses - General and administrative expenses are expected to be slightly lower in 2023 compared to 2022, focusing resources on NX-13 development [88]. - General and administrative expenses were $2.0 million for the three months ended June 30, 2023, compared to $4.7 million in 2022, a decrease of $2.7 million mainly due to lower compensation and recruiting costs [94]. Cash Flow - Net cash used in operating activities for the six months ended June 30, 2023, was $13.3 million, compared to $34.5 million in the same period of 2022 [101]. - Net cash provided by financing activities during the six months ended June 30, 2023, was $13.6 million, primarily from the issuance of pre-funded warrants [104]. - The company believes its existing cash and marketable securities will be sufficient to fund operations into the first half of 2025 [107]. Revenue Outlook - Future commercial revenue is expected to be derived from products not anticipated to be commercially available for several years, if at all [111]. - The company has not generated any revenue from product sales and does not expect to do so for at least the next few years [105]. Accounting and Reporting - There were no material changes to critical accounting policies and estimates during the six months ended June 30, 2023 [113]. - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures [114].